hotspot -WSS

hotspot

author：explore 2025-09-29 18:15:42 - browse：176

Have you ever seen a mouse with a set of muscles more appropriate for a bodybuilder or comic book superhero?

Well, 25 years ago, researchers at Johns Hopkins University made it happen. By silencing a gene responsible for producing a protein called myostatin, they directed tiny mouse bodies to grow double the amount of lean muscle they would normally, leading to mice with bulky arms, defined pectorals, and an overall more substantial body mass. They were dubbed “mighty mice.”

Now, biotech startups are hoping to use those findings to create what they believe will be better weight loss medications. In the last several months, multiple companies have disclosed they are testing drugs that preserve or grow muscle while reducing fat, as shown in the updated STAT Obesity Drug Tracker. They hope that their drugs, possibly when used in conjunction with existing obesity treatments, will result in healthier weight loss.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Wikipedia

WSS

AstraZeneca loses challenge to Medicare drug price negotiation

The EU Joint Clinical Assessment needs to live up to its promise

Biotech companies concerned about China biosecurity crackdown

Why getting cancer drugs just got harder for rural patients

Covid isolation guidance eased by the CDC

House looks to weaken Medicare negotiation

Wikipedia

hotspot

hotspot

Medical leaders decry Supreme Court decision on affirmative action

An inside look at PIPEs, biotech's buzzy new financing tool

Heart attack and stroke risk calculators need revising

Impact of Dobbs ruling felt at reproductive medicine meeting

Wildfire smoke exposes gaps in outdoor worker protections

Will Ozempic

In Memoriam: Notable people who died in 2023

STAT Summit: How a Chicago ER doctor tackles gun violence

Moonlake's readout produced a cash windfall. Risks remain

FogPharma raises $145 million in rare Series E round

Wikipedia

2023 STAT Wunderkinds: get to know the winners

Will Ozempic

Clinical trials giant ICON acquires HumanFirst

Senate committee scrutinizes Medicare Advantage brokers

Pfizer highlights cancer drugs it thinks could reignite investor interest

Clinical trials giant ICON acquires HumanFirst

knowledge

Wikipedia

knowledge

Wikipedia